open access
How to stop radiographic progression. Reimbursement of secukinumab in the B.82 drug program
Affiliations- Department and Clinic of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, Poland
open access
Abstract
In the past, axial spondyloarthropathies (axSpA) were considered synonymous with ankylosing spondylitis (AS). However, there is a group of patients who present clinical features of axSpA but do not have radiographic changes. Advances in medicine, especially diagnostic imaging and genetics, have made it possible to diagnose the disease at this earlier stage. For this group of patients, the concept of non-radiographic axSpA has been introduced.
It is already known that for patients with non-radiographic axSpA, as for those with AS, it is crucial to diagnose as soon as possible and initiate effective treatment, which causes the relief of clinical symptoms, but also is to prevent the progression of radiological changes. The introduction of tumor necrosis factor-alpha (TNFα) inhibitors changed the course of the disease and the prognosis of patients with axSpA. However, drugs with other mechanisms of action are being sought. One of the new drugs is secukinumab, which blocks interleukin-17 (IL-17), which is important in the pathogenesis of SpA. It has been shown that the majority of patients with nonradiographic axSpA treated with secukinumab did not show radiological progression.
The role of IL-17 blockade in the therapy of axSpA seems to be more appreciated, which was reflected in the updated global guidelines. Until recently, in Poland, only two drugs with the same mechanism of action — TNFα blockade (certolizumab pegol and etanercept) were reimbursed for patients with non-radiographic axSpA. Fortunately, from July 1, 2022, patients with non-radiographic axSpA can also receive IL-17 inhibitors (ixekizumab and secukinumab) in the B.82 drug program.
Abstract
In the past, axial spondyloarthropathies (axSpA) were considered synonymous with ankylosing spondylitis (AS). However, there is a group of patients who present clinical features of axSpA but do not have radiographic changes. Advances in medicine, especially diagnostic imaging and genetics, have made it possible to diagnose the disease at this earlier stage. For this group of patients, the concept of non-radiographic axSpA has been introduced.
It is already known that for patients with non-radiographic axSpA, as for those with AS, it is crucial to diagnose as soon as possible and initiate effective treatment, which causes the relief of clinical symptoms, but also is to prevent the progression of radiological changes. The introduction of tumor necrosis factor-alpha (TNFα) inhibitors changed the course of the disease and the prognosis of patients with axSpA. However, drugs with other mechanisms of action are being sought. One of the new drugs is secukinumab, which blocks interleukin-17 (IL-17), which is important in the pathogenesis of SpA. It has been shown that the majority of patients with nonradiographic axSpA treated with secukinumab did not show radiological progression.
The role of IL-17 blockade in the therapy of axSpA seems to be more appreciated, which was reflected in the updated global guidelines. Until recently, in Poland, only two drugs with the same mechanism of action — TNFα blockade (certolizumab pegol and etanercept) were reimbursed for patients with non-radiographic axSpA. Fortunately, from July 1, 2022, patients with non-radiographic axSpA can also receive IL-17 inhibitors (ixekizumab and secukinumab) in the B.82 drug program.
Keywords
secukinumab, inflammatory spondyloarthritides, non-radiographic form, interleukin-17
About this articleTitle
How to stop radiographic progression. Reimbursement of secukinumab in the B.82 drug program
Journal
Issue
Article type
Review paper
Pages
156-162
Published online
2022-12-31
Page views
3082
Article views/downloads
180
DOI
Bibliographic record
Rheumatology Forum 2022;8(4):156-162.
Keywords
secukinumab
inflammatory spondyloarthritides
non-radiographic form
interleukin-17
Authors
Dorota Sikorska
Włodzimierz Samborski
References (16)- Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011; 377(9783): 2127–2137.
- McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019; 78(9): 1167–1178.
- McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019; 50(4): 892–906.
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4): 361–368.
- Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009; 68(6): 777–783.
- Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol. 2010; 22(4): 375–380.
- Ciurea A, Kissling S, Bürki K, et al. Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort. RMD Open. 2022; 8(1): e002067.
- Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018; 14(6): 525–533.
- van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76(6): 978–991.
- Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019; 71(10): 1599–1613.
- Regel A, Sepriano A, Baraliakos X, et al. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017; 3(1): e000397.
- Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021; 73(1): 110–120.
- Braun J, Blanco R, Marzo-Ortega H, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021; 23(1): 231.
- Poster #POS0900 presented at EULAR Congress 2021.
- Poster #POS0299 presented at EULAR Congress 2022 Kopenhagen, 1-4 June 2022.
- Programy lekowe. https://www.gov.pl/web/zdrowie/programy-lekowe (18.09.2022).
